Fiche publication
Date publication
mars 2025
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe
Tous les auteurs :
Gavira J, Auclin E, Rey-Cardenas M, Roy P, Tapia JC, Nay P, Vinceneux A, Lefort F, Nannini S, Randis AMDC, Naoun N, Escudier B, Borchiellini D, de Velasco G, Barthelemy P, Gross-Goupil M, Negrier S, Oudard S, Frazer RD, Albiges L, Flippot R
Lien Pubmed
Résumé
Lenvatinib's activity after immune checkpoint inhibitors (ICI) combination therapy in renal cell carcinoma (RCC) remains unknown. We aimed to describe the real-world outcomes of patients with metastatic RCC (mRCC) treated with lenvatinib after failure of the prior standard of care.
Mots clés
Efficacy, Kidney cancer, Later lines, Lenvatinib, Outcomes, Real-world data, Renal Cell Carcinoma, Safety
Référence
Eur J Cancer. 2025 03 26;220:115389
